Liraglutide is a once-daily GLP-1 receptor agonist studied across more than 10,000 subjects in large randomized trials, and its timeline is unusually well documented as a result. The headline figure most people remember — the 8.0% average weight loss reported in the SCALE trial (Pi-Sunyer et al., 2015) — took 56 weeks to reach. The day-to-day arc is slower and more staged than that single number suggests, shaped by a 5-week dose titration from 0.6 mg up to 3.0 mg.
This timeline reports what clinical trials and community sources have documented at each phase, from the first daily injection through six months. It is not a schedule to follow. Individual response varied widely in trials by starting weight, glycemic status, tolerability of the titration, and concurrent diet and activity.
Research-context information only. Liraglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Liraglutide's timeline cannot be separated from its dosing schedule. Trial protocols for weight management used a fixed 5-week step-up: 0.6 mg in week 1, then +0.6 mg each week to reach 3.0 mg by week 5 (Pi-Sunyer et al., 2015). The escalation exists because GLP-1 receptors in the GI tract need time to adapt; trial data tied skipping steps to substantially higher nausea and discontinuation.
The practical consequence is that the first month of any liraglutide protocol is spent below the full weight-management dose. Pharmacology reviews note liraglutide binds albumin and carries an elimination half-life near 13 hours, supporting once-daily dosing and steady-state levels within a few days of each dose step (Sisson, 2011). So each weekly increment produces its own short adjustment period rather than a single ramp.
Week 1: Starting Dose, First Appetite Signal
The first week sits at 0.6 mg — a starting dose trial protocols described as sub-therapeutic for weight loss, used to establish tolerability rather than to drive results (Pi-Sunyer et al., 2015).
What trials documented:
0.6 mg daily as the initial titration step, not the weight-management target
Reduced appetite reported by many subjects even at this starting dose, consistent with liraglutide's central action on hypothalamic satiety signaling
GI effects — nausea most commonly — concentrated in the hours after early injections in the SCALE trial (Pi-Sunyer et al., 2015)
What community sources describe:
Self-reported community timelines commonly describe noticeably smaller portions and reduced food preoccupation within the first several days
Mild, transient nausea around the first injections is the most consistent community report at this stage
What was not documented this early: measurable scale weight loss attributable to liraglutide. Any change in the first week reflects appetite and fluid shifts, not the body-composition effect the trials measured over months.
Weeks 2 through 4 cover the 1.2 mg, 1.8 mg, and 2.4 mg steps. This is the most variable stretch of the timeline because each increment can briefly reintroduce GI effects before they settle (Pi-Sunyer et al., 2015).
What trials documented:
Stepwise dose increases of 0.6 mg per week, with the escalation central to tolerability in the SCALE protocol
Nausea as the most common adverse event, peaking during dose escalation and improving in most subjects over the following weeks (Pi-Sunyer et al., 2015)
Early, modest weight reduction beginning to appear in the liraglutide arm as the dose rose, though well short of the trial's final figures
What community sources describe:
Community reports cluster around appetite suppression strengthening with each dose step
Users in community sources commonly describe a temporary return of mild nausea on the day or two after each increase, then settling
Realistic framing: by the end of week 4, subjects in the SCALE protocol were approaching but had not yet reached the 3.0 mg target. The trial's weight-loss curve was still early on its climb.
Months 1-2: Reaching Full Dose
By week 5 the SCALE protocol reached the 3.0 mg weight-management target, and the first two months are where the documented weight-loss trajectory becomes clearer (Pi-Sunyer et al., 2015).
What trials documented:
3.0 mg daily as the full weight-management dose, reached at week 5 and maintained thereafter
A steadily accumulating weight-loss curve through the early months, contributing to the 8.0% average eventually reported at 56 weeks (Pi-Sunyer et al., 2015)
In subjects with type 2 diabetes, the SCALE Diabetes trial documented HbA1c and fasting-glucose improvements alongside weight loss over the trial period (Davies et al., 2015)
What community sources describe:
Self-reported community timelines describe the most consistent week-over-week scale movement starting once the full dose is held
The most consistent community feedback is that GI side effects have usually settled by this stage for those who tolerated the titration
Realistic framing: the trial defined a 5% body-weight loss as the clinically meaningful threshold, and most liraglutide subjects who reached it did so over roughly the first 12-16 weeks rather than the first month (Pi-Sunyer et al., 2015).
Months 3-6: Where Most Weight Loss Accrued
Months 3 through 6 are where the bulk of the SCALE weight-loss curve was documented before it began to flatten toward the 56-week endpoint.
What trials documented:
Continued weight loss through the first 6-9 months on 3.0 mg before the curve approached plateau, building toward the final 8.0% average versus 2.6% with placebo (Pi-Sunyer et al., 2015)
63.2% of liraglutide subjects losing at least 5% of body weight and 33.1% losing at least 10% by week 56, versus 27.1% and 10.6% on placebo (Pi-Sunyer et al., 2015)
In the LEADER cardiovascular outcomes trial of 9,340 subjects with type 2 diabetes, glycemic improvements were documented within months, while the cardiovascular-event separation emerged over a median 3.8-year follow-up (Marso et al., 2016)
What community sources describe:
Community reports cluster around slowing month-over-month weight loss in this window — steady but smaller decrements than the early-dose period
Users in community sources commonly describe weight regain after discontinuation, consistent with the trials' design as long-term continuous use rather than a short course
Realistic framing: the cardiovascular and renal signals associated with liraglutide in LEADER were documented over years of continuous use, not the first six months (Marso et al., 2016). The early timeline is dominated by appetite and weight effects; the outcomes data operate on a much longer horizon.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Factors That Affect Results
Several variables shifted the documented timeline across trial populations and community reports.
Faster or larger documented response:
Higher starting body weight — the SCALE trial reported larger absolute losses in heavier subjects (Pi-Sunyer et al., 2015)
Early appetite response — trial protocols treated early appetite suppression as a partial predictor of longer-term weight loss
Concurrent reduced-calorie diet and increased activity, which the SCALE protocol paired with the drug in all arms (Pi-Sunyer et al., 2015)
Slower or smaller documented response:
Difficulty completing the titration due to GI effects, which kept some subjects below the 3.0 mg target
Inconsistent daily dosing — liraglutide's ~13-hour half-life means missed days reduce steady-state exposure (Sisson, 2011)
Type 2 diabetes status, where the SCALE Diabetes trial documented somewhat smaller average weight loss than in subjects without diabetes (Davies et al., 2015)
The single largest variable in trial data was reaching and maintaining the full 3.0 mg dose. The weight-management figures the trials reported were tied to that dose, not the lower titration steps.
When Trials and Labeling Described Adjustment
Trial protocols and product labeling described several decision points along the timeline.
Early appetite signal: trial protocols framed reduced appetite in the first weeks as a partial early predictor of response, but not a guarantee — subjects with a strong early signal still varied at 56 weeks (Pi-Sunyer et al., 2015).
Tolerability at a dose step: when nausea was severe at a given titration step, protocols described holding the current dose for an extra week before increasing rather than pushing through. When 3.0 mg was not tolerated, the highest tolerated dose was maintained.
Limited weight response: product labeling describes reassessing whether to continue if a defined weight-loss threshold is not reached after several months on the full dose. This is a labeling parameter, not a self-directed instruction — a licensed physician makes that determination.
What if little changes: community reports describe a minority who see modest appetite change and little scale movement even at full dose. The trials documented a non-responder fraction, which is why the SCALE results are reported as population averages and responder percentages rather than a uniform outcome (Pi-Sunyer et al., 2015).
Frequently Asked Questions
How quickly did liraglutide work in trials?
Trial subjects commonly reported reduced appetite within the first 1-2 weeks, even at the starting 0.6 mg dose. Clinically meaningful weight loss (5%+ of body weight) was typically documented by 12-16 weeks. The SCALE trial (Pi-Sunyer et al., 2015) reported 8.0% average weight loss at 56 weeks.
What did the SCALE trial report at each stage of weight loss?
The SCALE trial (Pi-Sunyer et al., 2015) followed 3,731 subjects for 56 weeks on liraglutide 3.0 mg daily. Average weight loss reached 8.0% versus 2.6% with placebo by week 56, with 63.2% of liraglutide subjects losing at least 5% body weight. The trial described most weight loss accruing through the first 6-9 months before flattening.
Why does the 0.6 to 3.0 mg titration matter for early results?
Liraglutide trials used a 5-week step-up from 0.6 mg to 3.0 mg, adding 0.6 mg weekly. The escalation was designed to let GI-tract GLP-1 receptors adapt, and trial data tied skipping it to substantially higher nausea. During those first weeks subjects sat below the full weight-management dose, so the strongest appetite and weight effects were documented after titration completed.
What did glycemic trials report about liraglutide's timeline?
In the LEADER cardiovascular outcomes trial (Marso et al., 2016) of 9,340 subjects with type 2 diabetes, glucose and HbA1c improvements were documented within the first months, while the cardiovascular endpoint separation emerged over a median 3.8-year follow-up. The SCALE Diabetes trial (Davies et al., 2015) documented both weight and HbA1c improvement at 56 weeks.
What did trials report when subjects saw little response?
Trial protocols described early appetite response as a partial predictor of longer-term weight loss. When 3.0 mg was not tolerated, protocols maintained the highest tolerated dose rather than forcing the target. Product labeling describes reassessing continuation if a defined weight-loss threshold is not reached after several months. Consult a licensed physician for personal medical decisions.
Research Supplies for Liraglutide
Hand-picked storage, injection, and recovery supplies paired with Liraglutide protocols.
For educational and research purposes only. This is not medical advice. Liraglutide is an FDA-approved prescription medication — consult your healthcare provider for personalized guidance.
